Sosei has secured core products via its distinctive drug re-profiling platform (DRP), by in-licensing compounds at late-stage of development and through its internal R&D programmes in collaboration with biopharmaceutical companies and universities both in Japan and the West. The company has an active programme to add other promising drug candidates to its core product pipeline.
www.sosei.com